Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1139 Results

Title
Intervention Indication Therapeutic Area Year Actions
Risankizumab (by Subcutaneous Injection) for Moderate to Severe Chronic Plaque Psoriasis Risankizumab (BI 655066; Skyrizi; ABBV 066) Plaque psoriasis Dermatology 2017 View  |  Download
Risankizumab for moderate to severe crohn’s disease Risankizumab (BI 655066; Skyrizi; ABBV 066) Crohn's disease Gastroenterology , Immunology 2021 View  |  Download
Risankizumab for moderate to severe ulcerative colitis Risankizumab (BI 655066; Skyrizi; ABBV 066) Ulcerative colitis Gastroenterology 2022 View  |  Download
Risdiplam for paediatric and adult patients with spinal muscular atrophy (SMA) Risdiplam (RG-7916; RO-7034067; Evrysdi) Spinal muscular atrophy (SMA) Genetic Disorders , Musculoskeletal System 2019 View  |  Download
Ritlecitinib for alopecia areata Ritlecitinib (PF-06651600) Alopecia areata Dermatology , Immunology 2021 View  |  Download
Rituximab (MabThera) maintenance therapy for granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) Rituximab (MabThera; Rituxan; RG 105) Granulomatosis with polyangiitis (GPA) , Microscopic polyangiitis (MPA) Cardiovascular System 2017 View  |  Download
Rituximab for Pemphigus Vulgaris Rituximab (MabThera; Rituxan; RG 105) Pemphigus vulgaris Dermatology , Immunology 2018 View  |  Download
Rivaroxaban (Xarelto) in Combination with Aspirin for Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease Rivaroxaban (Xarelto; BAY 59-7939) Cardiovascular disease (CVD) Cardiovascular System 2017 View  |  Download
Rivaroxaban for prevention of cardiovascular events following an episode of decompensated heart failure Rivaroxaban (Xarelto; BAY 59-7939) Heart failure (HF) Cardiovascular System 2018 View  |  Download
Rivaroxaban for reducing the risk of major thrombotic vascular events in symptomatic peripheral arterial disease patients with a recent lower extremity revascularisation procedure Rivaroxaban (Xarelto; BAY 59-7939) Peripheral arterial disease (PAD) Cardiovascular System 2019 View  |  Download
1 2 86 87 88 89 90 113 114
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications